The DOI matches its Crossref record; 300 of the 302 references it cites were found in a registry or an index.
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Open accessAbstract
The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a central focus for engaging the immune system in the fight against cancer. Basic science discoveries elucidating the molecular and cellular biology of the T cell have led to new strategies in this fight, including checkpoint blockade, adoptive cellular therapy and cancer vaccinology. This area of immunological research has been highly active for the past 50 years and is now enjoying unprecedented bench-to-bedside clinical success. Here, we provide a comprehensive historical and biological perspective regarding the advent and clinical implementation of cancer immunotherapeutics, with an emphasis on the fundamental importance of T lymphocyte regulation. We highlight clinical trials that demonstrate therapeutic efficacy and toxicities associated with each class of drug. Finally, we summarize emerging therapies and emphasize the yet to be elucidated questions and future promise within the field of cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Conversely, myeloid-specific overexpression of HIF-1α results in hyperinflammatory, M1-polarized macrophages associated with increased glycolysis, suggesting a link between HIF-1α and M1-polarization [63].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [63]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The possible contribution of the adaptive immune system in AD patients to reducing cancer incidence has not been studied (4,5).”
From Alzheimer's Disease–Associated Amyloid-β Precursor Protein Prevents Aging Stress–Induced Mitophagy and Fumarate Depletion to Improve Antitumor Immunity (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“Typically, PD‐L1 or PD‐L2 are expressed on the surface of cancer cells or antigen‐presenting cells and transduce a signal for cooperation with PD‐1 expression on the cell surface of T lymphocytes to stimulate restraint signaling [272, 273].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [272]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Cited by
Sorted by citations
Items 201–300 of 1,006
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment
Hanahan, D., Michielin, O. A., & Pittet, M. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00761-z · Cited by 106
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
Wang, M., Yu, F., & Zhang, Y. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02214-5 · Cited by 110
Tumor organoid-immune co-culture models: exploring a new perspective of tumor immunity
Wang, J., Tao, X., Zhu, J., Dai, Z., Du, Y., Xie, Y., Chu, X., Fu, G., & Lei, Z. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02407-x · Cited by 101
3D Printing Scaffold Vaccine for Antitumor Immunity
Zhang, Y., Xu, J., Fei, Z., Dai, H., Fan, Q., Yang, Q., Chen, Y., Wang, B., & Wang, C. (2021) · Advanced Materials · doi:10.1002/adma.202106768 · Cited by 99
Role and Function of O-GlcNAcylation in Cancer
Lee, J. B., Pyo, K., & Kim, H. R. (2021) · Cancers · doi:10.3390/cancers13215365 · Cited by 103
Uldrick, T. S., Adams, S. V., Fromentin, R., Roche, M., Fling, S. P., Goncalves, P. H., Lurain, K. A., Ramaswami, R., Wang, C.-C. J., Gorelick, R. J., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl3836 · Cited by 100
Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies
Totzeck, M., Michel, L., Lin, Y., Herrmann, J., & Rassaf, T. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac106 · Cited by 103
Mesoporous Silica Materials as an Emerging Tool for Cancer Immunotherapy
Escriche‐Navarro, B., Escudero, A. C., Lucena‐Sánchez, E., Sancenón, F., García‐Fernández, A., & Martínez‐Máñez, R. (2022) · Advanced Science · doi:10.1002/advs.202200756 · Cited by 101
Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights
Kumar, S., Singh, S. K., Rana, B., & Rana, A. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.002 · Cited by 101
Recent advances in drug delivery systems for targeting brain tumors
Zhao, Y., Yue, P., Peng, Y., Sun, Y., Chen, X., Zhao, Z., & Han, B.-J. (2023) · Drug Delivery · doi:10.1080/10717544.2022.2154409 · Cited by 99
Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma
Calsina, B., Piñeiro-Yáñez, E., Martínez‐Montes, Á. M., Caleiras, E. J., Fernández-Sanromán, Á., Monteagudo, M., Torres‐Pérez, R., Torre, C. F., Pulgarín-Alfaro, M., Gil, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36769-6 · Cited by 103
Leveraging Aptamer-Based DNA Nanotechnology for Bioanalysis and Cancer Therapeutics
Huang, Z., Wang, D., Zhang, Q., Zhang, Y., Peng, R., & Tan, W. (2024) · Accounts of Materials Research · doi:10.1021/accountsmr.3c00249 · Cited by 96
Franken, A., Mol, P. V., Vanmassenhove, S., Donders, E., Schepers, R., Brussel, T. V., Dooms, C., Yserbyt, J., Crem, N. D., Testelmans, D., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005323 · Cited by 101
Zhang, S., Li, K., Dai, X., Chen, J., Chen, Z., Wang, M., Jiang, H., Wang, X., Bu, S., Liu, X., et al. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.10.004 · Cited by 100
Wang, N., Liu, C., Li, Y., Huang, D., Wu, X., Kou, X., Wang, X., Wu, Q., & Gong, C. (2023) · Nature Communications · doi:10.1038/s41467-023-36550-9 · Cited by 102
Current and promising applications of Hf( iv )-based MOFs in clinical cancer therapy
Chen, X., Li, M., Lin, M., Lu, C., Kumar, A., Pan, Y. H., Liu, J., & Peng, Y. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb00267e · Cited by 97
Massari, F., Rizzo, A., Mollica, V., Rosellini, M., Marchetti, A., Ardizzoni, A., & Santoni, M. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.06.015 · Cited by 96
The EBMT/EHA CAR-T Cell Handbook
Kröger, N., Gribben, J. G., Chabannon, C., Yakoub‐Agha, I., & Einsele, H. (2022) · Springer eBooks · doi:10.1007/978-3-030-94353-0 · Cited by 106
CD8 + T cell exhaustion in anti‐tumour immunity: The new insights for cancer immunotherapy
Huang, Y., Jia, A., Wang, Y., & Liu, G. (2022) · Immunology · doi:10.1111/imm.13588 · Cited by 96
Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy
Ebrahimi, N., Abdulwahid, A. R. R., Mansouri, A., Karimi, N., Bostani, R. J., Beiranvand, S., Adelian, S., Khorram, R., Vafadar, R., Hamblin, M. R., et al. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05098-8 · Cited by 101
Immune digital twins for complex human pathologies: applications, limitations, and challenges
Niarakis, A., Laubenbacher, R., An, G. C., Ilan, Y., Fisher, J., Flobak, Å., Reiche, K., Martínez, M. R., Geris, L., Ladeira, L., et al. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00450-5 · Cited by 104
The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy
Lee, J., Lozano‐Ruiz, B., Yang, F. M., Fan, D. D., Shen, L., & González-Navajas, J. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.625667 · Cited by 102
CRISPR screens for functional interrogation of immunity
Shi, H., Doench, J. G., & Chi, H. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00802-4 · Cited by 102
Modulating T Cell Responses by Targeting CD3
Menon, A. P., Moreno, B., Meraviglia-Crivelli, D., Nonatelli, F., Villanueva, H., Barainka, M., Zheleva, A., van Santen, H. M., & Pastor, F. (2023) · Cancers · doi:10.3390/cancers15041189 · Cited by 105
Emerging role of immunogenic cell death in cancer immunotherapy
Arimoto, K., Miyauchi, S., Liu, M., & Zhang, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1390263 · Cited by 103
Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities
Eddy, K., Shah, R., & Chen, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.626129 · Cited by 104
Wu, P., Han, J., Gong, Y., Liu, C., Yu, H., & Xie, N. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14101990 · Cited by 99
Engineered Living Materials for Advanced Diseases Therapy
Xue, D. Q., Wu, W. H., Pan, P., & Zhang, X. (2023) · Advanced Materials · doi:10.1002/adma.202304963 · Cited by 95
CAR T cells for treating autoimmune diseases
Blache, U., Tretbar, S., Koehl, U., Mougiakakos, D., & Fricke, S. (2023) · RMD Open · doi:10.1136/rmdopen-2022-002907 · Cited by 98
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
Tao, Z., Chyra, Z., Kotulová, J., Celichowski, P., Mihályová, J., Charvátová, S., & Hájek, R. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01193-6 · Cited by 101
Dugage, M. R., Nassif, E. F., Italiano, A., & Bahleda, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.775761 · Cited by 100
Tumor Microenvironment Shapes Colorectal Cancer Progression, Metastasis, and Treatment Responses
Li, J., Chen, D., & Shen, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.869010 · Cited by 97
Double enhancement of immunogenic cell death and antigen presentation for cancer immunotherapy
Xiong, X., Zhao, J., Su, R., Liu, C., Guo, X., & Zhou, S. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101225 · Cited by 94
Escaping Death: How Cancer Cells and Infected Cells Resist Cell-Mediated Cytotoxicity
Tuomela, K., Ambrose, A. R., & Davis, D. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867098 · Cited by 102
Wang, X., Jiang, Z., Xu, C., Meng, W.-Y., Liu, P., Zhang, Y., Xie, C., Xu, J., Xie, Y., Liang, T.-L., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106198 · Cited by 93
Role of CD68 in tumor immunity and prognosis prediction in pan-cancer
Zhang, J., Li, S., Liu, F., & Yang, K. (2022) · Scientific Reports · doi:10.1038/s41598-022-11503-2 · Cited by 92
Ling, Y., Zhong, J., Weng, Z., Lin, G., Liu, C., Pan, C., Yang, H., Wei, X., Xie, X., Wei, X., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1074 · Cited by 92
Immunotherapy in glioblastoma treatment: Current state and future prospects
Pinheiro, S. L. R., Lemos, F. F. B., Marques, H. S., Luz, M. S., Silva, L. G. D. O., dos Santos, C. F. S. M., Evangelista, K. D. C., Calmon, M. S., Loureiro, M. S., & de Melo, F. F. (2023) · World Journal of Clinical Oncology · doi:10.5306/wjco.v14.i4.138 · Cited by 99
Nanomaterial-enabled metabolic reprogramming strategies for boosting antitumor immunity
Ma, M., Zhang, Y., Pu, K., & Tang, W. (2024) · Chemical Society Reviews · doi:10.1039/d4cs00679h · Cited by 100
Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
Bian, X., Zhou, L., Luo, Z., Liu, G., Hang, Z., Li, H., Li, F., & Wen, Y. (2025) · ACS Nano · doi:10.1021/acsnano.4c11858 · Cited by 101
Thermo-responsive hydrogels for cancer local therapy: Challenges and state-of-art
Rafael, D. F. D. S., Roca-Melendres, M. M., Andrade, F., Montero, S., Martínez-Trucharte, F., Vilar-Hernández, M., Durán‐Lara, E. F., Schwartz, S., & Abasolo, I. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120954 · Cited by 93
The ambiguous role of obesity in oncology by promoting cancer but boosting antitumor immunotherapy
Assumpção, J. A. F., Pasquarelli-do-Nascimento, G., Viegas, M. S., Bonamino, M., & Magalhães, K. G. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00796-0 · Cited by 97
Interleukin 15 in Cell-Based Cancer Immunotherapy
Zhou, Y., Husman, T., Cen, X., Tsao, T., Brown, J., Bajpai, A., Li, M., Zhou, K., & Yang, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137311 · Cited by 92
Emerging Role of Glioma Stem Cells in Mechanisms of Therapy Resistance
Eckerdt, F., & Platanias, L. C. (2023) · Cancers · doi:10.3390/cancers15133458 · Cited by 96
Metal-Phenolic Nanomedicines Regulate T-Cell Antitumor Function for Sono-Metabolic Cancer Therapy
Yan, J., Li, W., Tian, H., Li, B., Yu, X., Wang, G., Sang, W., & Dai, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c02428 · Cited by 92
Engineered Bio‐Based Hydrogels for Cancer Immunotherapy
Peng, Y., Liang, S., Meng, Q., Liu, D., Ma, K., Zhou, M., Yun, K., Rao, L., & Wang, Z. (2024) · Advanced Materials · doi:10.1002/adma.202313188 · Cited by 91
He, J., Chai, X., Zhang, Q., Wang, Y., Wang, Y., Yang, X., Wu, J., Feng, B., Sun, J. P., Rui, W., et al. (2025) · Nature Immunology · doi:10.1038/s41590-024-02068-5 · Cited by 95
Robust delivery of RIG‐I agonists using extracellular vesicles for anti‐cancer immunotherapy
Peng, B., Nguyen, T. M., Jayasinghe, M. K., Gao, C. J., Pham, T. T., Vu, L. T., Yeo, E. Y. M., Yap, G. L. R., Wang, L., Goh, B. C., et al. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12187 · Cited by 90
Liu, R., Li, H., & Li, S. (2024) · Cell Insight · doi:10.1016/j.cellin.2024.100146 · Cited by 96
Nonsense-mediated RNA decay and its bipolar function in cancer
Nogueira, G., Fernandes, R. O., García-Moreno, J. F., & Romão, L. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01364-0 · Cited by 93
Lee, Y.-H., Lee, H. J., Kim, H. C., Lee, Y., Nam, S. K., Hupperetz, C., Ma, J. S. Y., Wang, X., Singer, O., Kim, W. S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.004 · Cited by 89
Nanomaterials Enhanced Sonodynamic Therapy for Multiple Tumor Treatment
Yang, M., Wang, X., Peng, M., Wang, F., Hou, S., Xing, R., & Chen, A. (2025) · Nano-Micro Letters · doi:10.1007/s40820-025-01666-8 · Cited by 96
DNA Logic Circuits for Cancer Theranostics
Chen, J., Fu, S., Zhang, C., Liu, H., & Su, X. (2022) · Small · doi:10.1002/smll.202108008 · Cited by 90
Biomarkers and targeted therapy for cancer stem cells
Liu, Y., & Wang, H. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.11.006 · Cited by 95
Harter, M. F., Recaldin, T., Gérard, R., Avignon, B., Bollen, Y., Esposito, C., Guja-Jarosz, K., Kromer, K., Filip, A. M., Aubert, J., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01156-5 · Cited by 93
Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy
Ghemrawi, R., Abuamer, L., Kremesh, S., Hussien, G., Ahmed, R., Mousa, W. K., Khoder, G., & Khair, M. (2024) · Biomedicines · doi:10.3390/biomedicines12092158 · Cited by 97
Immune-mediated drug-induced liver injury: immunogenetics and experimental models
Gerussi, A., Natalini, A., Antonangeli, F., Mancuso, C., Agostinetto, E., Barisani, D., Di Rosa, F., Andrade, R., & Invernizzi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094557 · Cited by 87
KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target
Yao, W., Ren, X., Galbo, P. M., Moerdler, S., Wang, H., Sica, R. A., Etemad-Gilbertson, B. A., Shi, L., Zhu, L., Tang, X.-D., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf9792 · Cited by 87
Metastasis-Entrained Eosinophils Enhance Lymphocyte-Mediated Antitumor Immunity
Grisaru‐Tal, S., Dulberg, S., Beck, L., Zhang, C., Itan, M., Hediyeh-zadeh, S., Caldwell, J. M., Rozenberg, P., Dolitzky, A., Avlas, S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0839 · Cited by 91
Organoid Models for Precision Cancer Immunotherapy
Sun, C., Lan, H., Fang, X., Yang, X., & Jin, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.770465 · Cited by 90
Polymer- and lipid-based gene delivery technology for CAR T cell therapy
Pinto, I. S., Cordeiro, R. A., & Faneca, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.038 · Cited by 89
CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy
Ghaffari, S., Khalili, N., & Rezaei, N. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02076-5 · Cited by 91
Chamseddine, A. N., Assi, T., Mir, O., & Chouaïb, S. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107986 · Cited by 89
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
Aparicio, C., Belver, M., Enríquez, L., Espeso, F., Núñez, L., Sánchez, A., de la Fuente, M. Á., & González‐Vallinas, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111781 · Cited by 118
Sorrentino, C., D’Antonio, L., Fieni, C., Ciummo, S. L., & Carlo, E. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.778329 · Cited by 92
Persson, M. L., Douglas, A. M., Alvaro, F., Faridi, P., Larsen, M. R., Alonso, M. M., Vitanza, N. A., & Dun, M. D. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac117 · Cited by 85
Kirchhammer, N., Trefny, M. P., Natoli, M., Brücher, D., Smith, S. N., Werner, F., Koch, V., Schreiner, D., Bartoszek, E. M., Buchi, M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm9043 · Cited by 86
Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy
CHEN, Q., GUO, X., & Ma, W. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.042383 · Cited by 86
Beyond energy storage: roles of glycogen metabolism in health and disease
Zhang, H., Ma, J., Tang, K., & Huang, B. (2020) · FEBS Journal · doi:10.1111/febs.15648 · Cited by 88
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
Punekar, S. R., Shum, E., Grello, C., Lau, S. C. M., & Velcheti, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877594 · Cited by 89
Pandit, M., Kil, Y., Ahn, J.-H., Pokhrel, R. H., Gu, Y., Mishra, S. K., Han, Y., Ouh, Y., Kang, B., Jeong, M. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38316-9 · Cited by 90
Nair, R., Somasundaram, V., Kuriakose, A., Krishn, S. R., Raben, D., Salazar, R. L., & Nair, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1548234 · Cited by 100
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine
Herati, R. S., Knorr, D. A., Vella, L. A., Silva, L. V., Chilukuri, L., Apostolidis, S. A., Huang, A. C. C., Muselman, A., Manne, S., Kuthuru, O., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01274-3 · Cited by 82
Leveraging Semiconducting Polymer Nanoparticles for Combination Cancer Immunotherapy
Wu, J., & Pu, K. (2023) · Advanced Materials · doi:10.1002/adma.202308924 · Cited by 88
Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis
Li, B., Elsten-Brown, J., Li, M., Zhu, E., Li, Z., Chen, Y., Kang, E., Ma, F., Chiang, J., Li, Y.-R., et al. (2025) · Cell · doi:10.1016/j.cell.2025.04.032 · Cited by 91
Immunocompetent cancer-on-chip models to assess immuno-oncology therapy
Maulana, T. I., Kromidas, E., Wallstabe, L., Cipriano, M., Alb, M., Zaupa, C., Hudecek, M., Fogal, B., & Loskill, P. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.015 · Cited by 86
Liu, L., Chen, J., Zhang, H., Ye, J., Moore, C., Lu, C., Fang, Y., Fu, Y., & Li, B. (2022) · Nature Cancer · doi:10.1038/s43018-022-00352-7 · Cited by 86
Wang, Z., Zhang, X., Lu, S., Zhang, C., Ma, Z., Su, R. J., Li, Y., Sun, T., Li, Y., Hong, M., et al. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00218-w · Cited by 87
Cellular and molecular waypoints along the path of T cell exhaustion
Lan, X., Zebley, C. C., & Youngblood, B. (2023) · Science Immunology · doi:10.1126/sciimmunol.adg3868 · Cited by 87
Untangling the web of intratumour heterogeneity
Li, Z., Seehawer, M., & Polyák, K. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00969-x · Cited by 82
Ren, F., Wang, F., Baghdasaryan, A., Li, Y., Liu, H., Hsu, R., Wang, C., Li, J., Zhong, Y., Salazar, F. B., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01083-5 · Cited by 85
Kerns, S. J., Belgur, C., Petropolis, D., Kanellias, M., Barrile, R., Sam, J., Weinzierl, T., Fauti, T., Freimoser-Grundschober, A., Eckmann, J., et al. (2021) · eLife · doi:10.7554/elife.67106 · Cited by 82
The emerging role of leukemia inhibitory factor in cancer and therapy
Zhang, C., Liu, J., Wang, J., Hu, W., & Feng, Z. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107754 · Cited by 82
EGFR-Targeted Photodynamic Therapy
Ulfo, L., Costantini, P. E., Giosia, M. D., Danielli, A., & Calvaresi, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020241 · Cited by 83
Construction of tumor organoids and their application to cancer research and therapy
Lv, J., Du, X., Wang, M., Su, J., Wei, Y., & Xu, C. (2024) · Theranostics · doi:10.7150/thno.91362 · Cited by 90
Repurposing anticancer drugs for the management of COVID-19
Bairi, K. E., Trapani, D., Petrillo, A., Page, C. L., Zbakh, H., Daniele, B., Belbaraka, R., Curigliano, G., & Afqir, S. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.014 · Cited by 82
Modulation of the tumor microenvironment (TME) by melatonin
Qi, M., & Najafi, M. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174365 · Cited by 82
A DNA/DMXAA/Metal–Organic Framework Activator of Innate Immunity for Boosting Anticancer Immunity
Chen, X., Tang, Q., Wang, J., Zhou, Y., Li, F., Xie, Y., Wang, X., Du, L., Li, J., Pu, J., et al. (2023) · Advanced Materials · doi:10.1002/adma.202210440 · Cited by 81
Cancer Nanovaccines: Nanomaterials and Clinical Perspectives
Desai, N., Chavda, V. P., Singh, T. R. R., Thorat, N. D., & Vora, L. K. (2024) · Small · doi:10.1002/smll.202401631 · Cited by 83
Luo, Z., Mei, J., Wang, X., Wang, R., He, Z., Geffen, Y., Sun, X., Zhang, X., Xu, J., Wan, R., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114697 · Cited by 85
Ying, X., Chen, Q., Yang, Y., Wu, Z., Zeng, W., Miao, C., Huang, Q., & Ai, K. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02186-6 · Cited by 87
Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy
Isser, A., Livingston, N. K., & Schneck, J. P. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120584 · Cited by 77
Li, S., Chen, J. Y., & Sun, Z. (2021) · 癌症：英文版 · doi:10.1002/cac2.12183 · Cited by 79
Su, T., Cheng, F., Qi, J., Zhang, Y. X., Zhou, S., Mei, L., Fu, S., Zhang, F., Lin, S., & Zhu, G. (2022) · Advanced Science · doi:10.1002/advs.202201895 · Cited by 78
Engineered cell entry links receptor biology with single-cell genomics
Yu, B., Shi, Q., Belk, J. A., Yost, K. E., Parker, K. R., Li, R., Liu, B. B., Huang, H., Lingwood, D., Greenleaf, W. J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.11.016 · Cited by 87
Rise of the natural red pigment ‘prodigiosin’ as an immunomodulator in cancer
Anwar, M. M., Albanese, C., Hamdy, N. Μ., & Sultan, A. S. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02815-4 · Cited by 81
Expansion of interferon inducible gene pool via USP18 inhibition promotes cancer cell pyroptosis
Arimoto, K., Miyauchi, S., Troutman, T. D., Zhang, Y., Liu, M., Stoner, S. A., Davis, A. G., Fan, J.-B., Huang, Y.-J., Yan, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35348-5 · Cited by 83
Biomaterial-based platforms for tumour tissue engineering
Curvello, R., Kast, V., Ordóñez‐Morán, P., Mata, Á., & Loessner, D. (2023) · Nature Reviews Materials · doi:10.1038/s41578-023-00535-3 · Cited by 82
DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs
Guo, H., Vuille, J. A., Wittner, B. S., Lachtara, E. M., Hou, Y., Lin, M., Zhao, T., Raman, A. T., Russell, H. C., Reeves, B. A., et al. (2023) · Cell · doi:10.1016/j.cell.2023.05.028 · Cited by 83
Chen, Z., Zhang, G., Ren, X., Yao, Z., Zhou, Q., Ren, X., Chen, S., Xu, L., Sun, K., Zeng, Q., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0193 · Cited by 83
Metadata
- Authors
- Waldman, A. D., Fritz, J. M., & Lenardo, M. J.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Lenardo, Michael J.
- Venue
- Nature Reviews Immunology
- Published
- 2020-05-20
- Volume
- 20
- Issue
- 11
- Pages
- 651-668
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC7238960
- OpenAlex
- W3028523516
- Cited by
- 4,154
- References
- 302
- Citations by year
- 2026: 382 · 2025: 748 · 2024: 867 · 2023: 824 · 2022: 754 · 2021: 511 · 2020: 59
- FWCI
- 58.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- Emory University
- National Institutes of Health
- National Institute of General Medical Sciences (T32GM008169)
- National Institute of Allergy and Infectious Diseases
- NHLBI Division of Intramural Research
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cancer immunotherapy, T cells, T cell regulation, immune checkpoint blockade, adoptive cellular therapy, clinical trials, immunotherapy toxicity, history of cancer immunotherapy
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Clinical Trials as Topic, Humans, Immunotherapy, Neoplasms, T-Lymphocytes, Immunotherapy, Adoptive, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
